Programmable RNA therapeutics: converging vaccination and on-demand disease treatment via self-adaptive RNA platforms
- 1Department of Research, Publication and Extension, Kampala International University
Abstract
RNA technology, most prominently messenger RNA (mRNA), has transformed vaccine development by enabling rapid, sequence-specific antigen design, scalable manufacturing, and transient protein expression. Its long-term significance, however, extends beyond prophylactic vaccination. This Perspective argues that mRNA should be conceptualised as a programmable therapeutic platform capable of integrating vaccination, immune modulation, and on-demand disease treatment. Current mRNA vaccines deliver predefined antigenic instructions, whereas emerging RNA systems, including self-amplifying RNA (saRNA), circular RNA, sequence-engineered mRNA, and targeted lipid nanoparticles (LNPs), may support more adaptable therapeutic functions. Such platforms could prime immunity, replace deficient proteins, encode antibodies, reprogramme immune cells, or induce antigen-specific tolerance. The concept of self-adaptive RNA-based therapeutics remains at an early stage and should not be overstated; most existing systems are programmable at the design stage rather than biologically autonomous after administration. Nonetheless, this conceptual position is no longer purely speculative: the first regulatory approval of a self-amplifying RNA vaccine and controlled-trial evidence of clinical benefit from a personalised neoantigen mRNA therapeutic in resected melanoma indicate that programmable RNA platforms are beginning to move from concept to clinical validation across both the prophylactic and therapeutic ends of the spectrum. Key challenges include tissue-specific delivery, expression control, innate immune activation, repeat dosing, safety assessment, regulatory classification, and equitable access. A self-adaptive RNA-based framework does not replace existing vaccines or biologics but extends them towards responsive, personalised, and temporally controlled therapy.
Related
- Engineered mRNA nanostructures expand the design space of mRNA therapeutics through programmable protein expression and immune stimulation
- ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
- Do God Primes Prime God? Converging Evidence Against the Efficacy of Experimental Religious Priming
- Converging Paths: Artificial Intelligence for Integrating Biological and Digital Biomarkers in Personalized Longevity Medicine
- Network analysis reveals converging molecular mechanisms in genetic epilepsies
BibTeX
@article{ugwu2026programmable,
title = {{Programmable RNA therapeutics: converging vaccination and on-demand disease treatment via self-adaptive RNA platforms}},
author = {Okechukwu Paul-Chima Ugwu and Michael Ben Okon and Fabian Chukwudi Ogenyi and Jovita Nnenna Ugwu and Chinyere N. Ugwu},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1872123},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1872123/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Programmable RNA therapeutics: converging vaccination and on-demand disease treatment via self-adaptive RNA platforms
AU - Okechukwu Paul-Chima Ugwu
AU - Michael Ben Okon
AU - Fabian Chukwudi Ogenyi
AU - Jovita Nnenna Ugwu
AU - Chinyere N. Ugwu
PY - 2026
DA - 2026/10/29
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1872123
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1872123/full
AB - RNA technology, most prominently messenger RNA (mRNA), has transformed vaccine development by enabling rapid, sequence-specific antigen design, scalable manufacturing, and transient protein expression. Its long-term significance, however, extends beyond prophylactic vaccination. This Perspective argues that mRNA should be conceptualised as a programmable therapeutic platform capable of integrating vaccination, immune modulation, and on-demand disease treatment. Current mRNA vaccines deliver predefined antigenic instructions, whereas emerging RNA systems, including self-amplifying RNA (saRNA), circular RNA, sequence-engineered mRNA, and targeted lipid nanoparticles (LNPs), may support more adaptable therapeutic functions. Such platforms could prime immunity, replace deficient proteins, encode antibodies, reprogramme immune cells, or induce antigen-specific tolerance. The concept of self-adaptive RNA-based therapeutics remains at an early stage and should not be overstated; most existing systems are programmable at the design stage rather than biologically autonomous after administration. Nonetheless, this conceptual position is no longer purely speculative: the first regulatory approval of a self-amplifying RNA vaccine and controlled-trial evidence of clinical benefit from a personalised neoantigen mRNA therapeutic in resected melanoma indicate that programmable RNA platforms are beginning to move from concept to clinical validation across both the prophylactic and therapeutic ends of the spectrum. Key challenges include tissue-specific delivery, expression control, innate immune activation, repeat dosing, safety assessment, regulatory classification, and equitable access. A self-adaptive RNA-based framework does not replace existing vaccines or biologics but extends them towards responsive, personalised, and temporally controlled therapy.
SN - 1664-3224
ER -